Key result
Rivaroxaban or apixaban exposure significantly reduced TRAP-induced platelet aggregation at 2 hours compared to baseline (29.51% vs 56.15%; P=.000).
Why the study?
Do apixaban or rivaroxaban reduce TRAP-induced platelet aggregation in patients with atrial fibrillation?
Observational (n=41)
No
Do apixaban or rivaroxaban reduce TRAP-induced platelet aggregation in patients with atrial fibrillation?
Absolute Event Rate: 29.51% vs 56.15%
p-value: p=.000
Rivaroxaban and apixaban significantly reduce TRAP-induced platelet aggregation 2 hours post-dose, suggesting an additional antiplatelet effect beyond factor Xa inhibition.
The availability of direct oral anticoagulants has caused a paradigm shift in the management of thrombosis. Rivaroxaban and apixaban are 2 direct oral anticoagulants whose target specificity is activated factor X (FXa). However, it is still not fully understood if and how xabans impact platelet function. This observational study aimed to assess the in vitro platelet function in patients with atrial fibrillation receiving xabans. This was a single-center study quantifying platelet aggregation in 41 patients treated with apixaban or rivaroxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 hours after taking rivaroxaban or apixaban compared to baseline value (56.15% [8.53%] vs 29.51% [12.9%]; P = .000). Moreover, concomitant use of angiotensin-converting enzyme blockers, proton pump inhibitors, and statins reduces the efficiency of xabans. The TRAP-induced platelet aggregation was reduced in patients with cardiovascular disease 2 hours after receiving xabans.
No takes yet. Share an insight, caveat, or question.
Neháj et al. (2017) conducted an observational in Atrial fibrillation (n=41). Rivaroxaban or apixaban vs. Baseline (prior to taking medication) was evaluated on TRAP-induced platelet aggregation (p=.000). Rivaroxaban or apixaban exposure significantly reduced TRAP-induced platelet aggregation at 2 hours compared to baseline (29.51% vs 56.15%; P=.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: